My Account

Risk Management
Workers Comp & Safety
Employee Benefits
International
People
Events
BI Intelligence
Magazine
- Current Issue
- Past Issues
DEI Institute

Recent Quotes

View Full List

My Watchlist

Indicators

Business Insurance Index

Markets:

Overview

News

Currencies

International

Treasuries

CymaBay Therapeutics Inc. - Common Stock (NQ:CBAY)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 21, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about CymaBay Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >

Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production ↗

March 15, 2024

Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yescarta and Tecartus, Gilead aims to diversify into oncology. Anticipating a...

Via Benzinga

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs ↗

March 14, 2024

As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Via Benzinga

CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst ↗

February 13, 2024

Gilead's acquisition of CymaBay Therapeutics for $4.3 billion strengthens its liver disease portfolio. Analysts see potential in seladelpar's impact on PBC and pruritus, projecting peak sales of $800...

Via Benzinga

Fear & Greed Index Remains In 'Extreme Greed' Zone Ahead Of Inflation Data; Dow Hits Record high ↗

February 13, 2024

The CNN Money Fear and Greed index remained in the "Extreme Greed" zone on Monday. U.S. stocks closed mixed on Monday, with the Dow Jones index climbing to a fresh high during the session.

Via Benzinga

Topics Economy Stocks

Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B ↗

February 12, 2024

U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded up 0.48% to 38,856.99 while the NASDAQ rose 0.26% to 16,031.87. The S&P 500...

Via Benzinga

Topics Stocks

6 Analysts Have This to Say About CymaBay Therapeutics ↗

December 15, 2023

Via Benzinga

Recap: CymaBay Therapeutics Q3 Earnings ↗

November 07, 2023

Via Benzinga

Dow Up Triple Digits, Hits Fresh Highs ↗

February 12, 2024

Stocks are on the rise today, as investors towards tomorrow's inflation data.

Via Talk Markets

Topics Economy Stocks

Why is CymaBay (CBAY) Stock Up 25% Today? ↗

February 12, 2024

CymaBay stock is rising higher on Monday as CBAY investors react to a $4.3 billion acquisition deal with Gilead Sciences.

Via InvestorPlace

CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday ↗

February 12, 2024

U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) rose sharply in today’s pre-market trading.

Via Benzinga

Topics Stocks

Health Care Company Gilead Sciences Announces Acquisition of CymaBay Therapeutics ↗

February 12, 2024

Via Benzinga

Earnings Outlook For CymaBay Therapeutics ↗

November 06, 2023

Via Benzinga

Where CymaBay Therapeutics Stands With Analysts ↗

November 06, 2023

Via Benzinga

Why CymaBay Therapeutics Stock Is Sinking This Week ↗

September 21, 2023

The stock has given up some of its gains but remains up more than 130% year to date.

Via The Motley Fool

Drugmaker Gilead Sciences Scoops Up Liver-Disease Focused CymaBay Therapeutics For $4.3B ↗

February 12, 2024

Gilead Sciences will acquire CymaBay Therapeutics for $4.3 billion, advancing liver disease treatment with seladelpar. FDA priority review was granted, and there is potential for significant revenue...

Via Benzinga

CymaBay Stock Rockets After Gilead Sciences Unveils $4.3 Billion Acquisition ↗

February 12, 2024

The company is working on a treatment for primary biliary cholangitis, a liver disease treatment.

Via Investor's Business Daily

Why CymaBay Morphed From Dollar Stock To Biotech Rocket ↗

December 28, 2023

The company is working on the first treatment that could make a difference in the itching associated with a liver disease.

Via Investor's Business Daily

Raymond James Maintains Strong Buy Rating for CymaBay Therapeutics: Here's What You Need To Know ↗

November 08, 2023

Via Benzinga

Why CymaBay Therapeutics Stock Rocketed Nearly 8% Higher Today ↗

October 23, 2023

It became increasingly likely that seladelpar will ultimately gain regulatory approval.

Via The Motley Fool

7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio ↗

September 27, 2023

Dive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game.

Via InvestorPlace

UBS Maintains Buy Rating for CymaBay Therapeutics: Here's What You Need To Know ↗

September 26, 2023

Via Benzinga

Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease ↗

September 21, 2023

Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due...

Via Benzinga

Why CymaBay Therapeutics Stock Triumphed Again on Tuesday ↗

September 12, 2023

The company is about to reap more money than previously expected from a new capital-raising effort.

Via The Motley Fool

Why CymaBay Therapeutics Stock Popped Again Today ↗

September 11, 2023

Days after it reported highly encouraging news from a clinical trial, the company announced a new round of capital-raising.

Via The Motley Fool

Why Hooker Furnishings Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

September 08, 2023

Gainers Biocept, Inc. (NASDAQ: BIOC) shares jumped 97.6% to $1.6608 after the company announced non-exclusive licensing agreement for CNSide with Plus Therapeutics.

Via Benzinga

Why CymaBay Therapeutics Stock Is Jumping Today ↗

September 08, 2023

The momentum continues after CymaBay reported great clinical results on Thursday.

Via The Motley Fool

Why CymaBay, With 172% Growth This Year, Just Surged For A Second Day Running ↗

September 08, 2023

The company is working on a treatment for a liver disease that can cause severe itching.

Via Investor's Business Daily

Smartsheet, Kroger, Lantronix And Other Big Stocks Moving Higher On Friday ↗

September 08, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording gains in today’s session. Lantronix, Inc. (NASDAQ: LTRX) shares jumped 26.3% to...

Via Benzinga

Topics Stocks

CymaBay Therapeutics' Lead Drug Candidate Hits Main Goal In Pivotal Study For Liver Damage ↗

September 07, 2023

CymaBay Therapeutics Inc (NASDAQ: CBAY) released topline results from its Phase 3 pivotal RESPONSE study of seladelpar for adult patients with

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 07, 2023

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.

Information

About Us
Contact
Advertise
Privacy Policy
Terms & Condition